Restore Relief with Mytesi

The First and Only Antisecretory, Antidiarrheal Agent

FDA approved for symptomatic relief of noninfectious diarrhea in
adults with HIV/AIDs on antiretroviral therapy (ART).

DISCOVER MYTESI

Chronic, noninfectious diarrhea can affect people living with HIV (PLWH)

1 in 4 patients with HIV
experienceS chronic diarrhea.1

Understanding the pathophysiology of noninfectious diarrhea in PLWH on ART, their experience, and the pharmacology of Mytesi can help you better serve your patients.

UNDERSTAND HIV & NONINFECTIOUS DIARRHEA

Mytesi may provide a solution for noninfectious diarrhea in PLWH on ART

Mytesi is a nonopiate, antisecretory medication that normalizes fluid and electrolyte balance in the gastrointestinal (GI) tract and provides symptomatic relief of diarrhea with a minimal risk of constipation.2-4

Mytesi demonstrated a significant decrease in diarrhea in the ADVENT clinical trial.2-4

There were no treatment interruptions or discontinuations due to Mytesi-related adverse events in clinical studies.2-4

SEE CLINICAL TRIAL DATA

Ask Every Patient

Diarrhea is common among PLWH, so it’s important to ask every patient about diarrhea. Studies show that long-term HIV survivors have higher rates of diarrhea, so prioritizing conversations with these patients is especially important to make the biggest impact.1,5

See Tips for Talking About Diarrhea

NapoCares™
helps patients access their prescription for Mytesi*

Napo Pharmaceuticals is committed to helping patients access Mytesi, whether they are uninsured, underinsured, or insured.

LEARN MORE ABOUT NAPOCARES™

*Subject to eligibility. Restrictions apply. Rx only.

References:
1. Online Survey of Patients Living with HIV (2017). Sponsored by Napo Pharmaceuticals. 2. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals. 2018. 3. MacArthur RD, Clay P, Blick G, Waltzman R, Bell M. Long-term Crofelemer provides clinically relevant reductions in HIV-related diarrhea. 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris, France. Abstract WEPEB0537. 4. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of Crofelemer for non-infectious diarrhea in HIV-seropositive individuals (ADVENT Trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261-273. 5. Hardwicke RL, Guthrie E, Chen HY, Grimes RM. Has diarrhea ceased to be a concern in persons living with HIV? Results from a cross-sectional study. J Assoc Nurses AIDS Care. 2021;32(5):e40-e45. doi:10.1097/JNC.0000000000000204